title: Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?
authors.forename: Ian
authors.initials: I
authors.lastname: Thornley
authors.forename: John P
authors.initials: JP
authors.lastname: Perentesis
authors.forename: Stella M
authors.initials: SM
authors.lastname: Davies
authors.forename: Franklin O
authors.initials: FO
authors.lastname: Smith
authors.forename: Martin
authors.initials: M
authors.lastname: Champagne
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Lipton
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002648:Child; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate